Key facts
- This page summarizes Robert E. Waltermire's Form 4 filing for MADRIGAL PHARMACEUTICALS, INC. (MDGL).
- 3 reported transactions and 1 derivative row are listed below.
- Accepted by SEC: 14 Jun 2024, 21:44.
Robert E. Waltermire - 12 Jun 2024 Form 4 Insider Report for MADRIGAL PHARMACEUTICALS, INC. (MDGL)
- Reporting relationship
- Senior VP, Chief Pharma Dev.
- Issuer ticker
- MDGL
- Reported as of
- 12 Jun 2024
- Net transaction value
- -$394,160
- SEC form
- 4
- Accepted by SEC
- 14 Jun 2024, 21:44:36 UTC
- Prior SEC filing
- 23 May 2024
- Next SEC filing
- 18 Jun 2024
- Source filing
- View source filing
- Reporting owner signature
- /s/ Mardi Dier, as Attorney-in-Fact
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Robert E. Waltermire filed Form 4 for MADRIGAL PHARMACEUTICALS, INC. (MDGL) on 14 Jun 2024.
Change
- Previous filing in this sequence was filed on 23 May 2024.
- Current net transaction value: -$394,160.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
MDGL
transaction
Common Stock
Options Exercise
- Transaction value
- $175,840
- Shares
- +2,000
- Change %
- +36%
- Price
- $87.92
- Shares after
- 7,500
- Date
- 12 Jun 2024
- Ownership
- Direct
- Footnotes
- F1
MDGL
transaction
Common Stock
Sale
- Transaction value
- $570,000
- Shares
- -2,000
- Change %
- -27%
- Price
- $285.00
- Shares after
- 5,500
- Date
- 12 Jun 2024
- Ownership
- Direct
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
MDGL
transaction
Derivative
Stock Option (Right to Buy)
Options Exercise
- Transaction value
- $0
- Shares
- -2,000
- Change %
- -12%
- Price
- $0.000000
- Shares after
- 15,200
- Date
- 12 Jun 2024
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 2,000
- Exercise price
- $87.92
- Footnotes
- F1
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 1 footnote
Footnote F1
All shares issued pursuant to the exercise of the options reported herein represent 2,000 shares underlying an overall option award of 35,000 shares. All exercised options had vested. As to the overall option for 35,000 shares, 25% of the shares underlying the option vested on August 2, 2022 and, thereafter, 6.25% of the shares vested, or will vest, on the last day of each successive three-month period, provided the Reporting Person continues in service with the Issuer on each such date.